AllianceBernstein
KYTX icon

AllianceBernstein’s Kyverna Therapeutics KYTX Stock Holding History

AllianceBernstein’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$191K Buy
+22,100
New +$196K ﹤0.01% 3161
2025
Q2 		– Sell
-30,010
Closed -$57.9K – 3354
2025
Q1 		$57.9K Hold
30,010
– – ﹤0.01% 3116
2024
Q4 		$112K Hold
30,010
– – ﹤0.01% 3116
2024
Q3 		$147K Buy
30,010
+4,300
+17% +$33.2K ﹤0.01% 3081
2024
Q2 		$193K Sell
25,710
-450,117
-95% -$6.88M ﹤0.01% 3045
2024
Q1 		$11.8M Buy
+475,827
New +$13.3M ﹤0.01% 1075

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

AllianceBernstein's KYTX Position: Q2 2026 in Review

AllianceBernstein opened a new position in Kyverna Therapeutics (KYTX) in Q2 2026: 22,100 shares worth $191K. The stake represents ﹤0.01% of the portfolio and ranks #3161 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in KYTX as recently as Q1 2025.

AllianceBernstein first reported a position in KYTX in Q1 2024 and has held it in 6 quarters since. The position peaked at $11.8M in Q1 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • AllianceBernstein held 22,100 shares of Kyverna Therapeutics worth $191K as of Q2 2026.
  • Kyverna Therapeutics was a new AllianceBernstein position in Q2 2026.
  • Kyverna Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3161 holding.
  • AllianceBernstein first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • AllianceBernstein's Kyverna Therapeutics position peaked at $11.8M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.